Sushant Kumar, PhD, is an accomplished professional in the biotechnology and pharmaceutical industries with extensive experience in research and development, business development, and investment management. Currently serving as an R&D and Business Development Advisor at BioSapient LLC and Managing Director at Edison Group since April 2017, Sushant has also founded and led Tarus Therapeutics as President & CEO, where innovative adenosine receptor antagonists were developed. Previous positions include Co-Founder and CEO of GCATx, focusing on genomically-defined cancers, and Co-Founder and Managing Partner at Ardana Capital Management, specializing in investments in novel healthcare companies. Sushant's early career included a partnership at Mehta Partners, contributing to significant transactions within the BioPharma sector. Educationally, Sushant earned a PhD in Molecular Biology from Rutgers Robert Wood Johnson Medical School and completed a post-doctoral fellowship at Harvard Medical School, focusing on targeted protein degradation mechanisms.
This person is not in any teams
This person is not in any offices